Breast cancer patients treated with chemotherapy show improved executive function after cognitive training

NewsGuard 100/100 Score

Women whose breast cancer had been treated with chemotherapy demonstrated improved executive function, such as cognitive flexibility, verbal fluency and processing speed after using exercises developed by Lumosity, the leading online cognitive training program. The study also found significant improvement in self-reported measures of everyday executive function and observed some transfer to verbal memory. Researchers at Stanford University published the results in the peer-reviewed journal, Clinical Breast Cancer. Dr. Shelli Kesler, Assistant Professor of Psychiatry and Behavioral Sciences at Stanford University is the lead author of the study.

Studies have found that chemotherapy causes changes in brain structure and function. The most common effects of the cognitive impairment associated with cancer treatment include memory, processing speed and attention. Up to 75 percent of women who have undergone chemotherapy for breast cancer treatment experience long-term cognitive deficits that significantly reduce quality of life.

"The most common quality-of-life complaint from breast cancer survivors is the cognitive effect of cancer treatments," said Joe Hardy, Ph.D, VP of Research & Development at Lumosity. "These results are interesting because they suggest that online cognitive training shows promise as an intervention for cognitive difficulties in breast cancer survivors, and even long-term survivors can benefit."

The study included 41 breast cancer survivors who were randomly assigned to the active treatment group>

The effects of the Lumosity training program were measured by conducting a pre-test before and a post-test after completion of the training program using psychometrically validated and standardized cognitive tests. The active treatment group experienced significantly larger gains on measures of executive function, word finding and processing speed, and a trending improvement on verbal memory, compared to the waitlist control group. The active group also showed reduced self-rated symptoms of everyday executive function problems.

The study is in press in the May online edition of Clinical Breast Cancer and will appear in an upcoming print edition of the journal. Study authors do not have any financial relationship or other conflicts of interest with Lumosity.

"We're committed to helping people from all walks of life improve their core cognitive abilities, and we're excited that this study has shown very promising results for a real-world clinical application of cognitive training for cancer survivors," said Hardy. "We've created Lumosity to be an accessible tool for anyone who wants to train their brain, as well as researchers who want to study the effects of cognitive training on specific populations."

Lumosity's research program, the Human Cognition Project, works with researchers worldwide to study human cognitive performance. The technology supports both experimental research, where independent researchers design and conduct studies on the effects of computerized cognitive training, and observational research, where collaborators explore data from Lumosity's database of 40 million people.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery